AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29040974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab and Bevacizumab with Gemcitabine
Number of subjects: 127
Study 26812509 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based computerized cognitive training (CCT) 3x/week for 6 weeks, average of 23 minutes/session
Number of subjects: 44
Study 26812509 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study 25017114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI), 15 °C to umbilicus
Number of subjects: 74
Study 25017114 — intervention group
Group type: EXPERIMENTAL
Intervention: Iced-slush ingestion (SLUSH), 7 g·kg(‐1) body weight
Number of subjects: 74
Study 25017114 — intervention group
Group type: COMPARATOR
Intervention: Seated rest (CONT)
Number of subjects: 74
Study 20851629 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 75
Study 19654384 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group (n=3271) using the Woman Abuse Screening Tool (WAST) before the health care visit.
Number of subjects: 6743
Study 19654384 — intervention group
Group type: COMPARATOR
Intervention: Nonscreened group (n=3472) using the WAST and other measures after their visit.
Number of subjects: 6743
Study 19654384 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group (n=3271)
Number of subjects: 6743
Study 19654384 — intervention group
Group type: COMPARATOR
Intervention: Nonscreened group (n=3472)
Number of subjects: 6743
Study 17208671 — intervention group
Group type: EXPERIMENTAL
Intervention: Clens 100
Number of subjects: 22
Study 17208671 — intervention group
Group type: COMPARATOR
Intervention: Blink‐N‐Clean
Number of subjects: 22
Study 17208671 — intervention group
Group type: COMPARATOR
Intervention: No product
Number of subjects: 22
Study 16342084 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis Self‐Management Program (ASMP)
Number of subjects: 355
Study 16342084 — intervention group
Group type: COMPARATOR
Intervention: Chronic Disease Self‐Management Program (CDSMP)
Number of subjects: 355
Study 11989042 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 45
Study 11989042 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 45
Study 9882992 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (Group A)
Number of subjects: 33
Study 9882992 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group B)
Number of subjects: 33
Study 8556970 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine 400 mg daily
Number of subjects: 50
Study 8556970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1977949 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized beta 2‐agonists only
Number of subjects: 55
Study 1977949 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerosolized beta 2‐agonists with intravenous AMP
Number of subjects: 55
Study 1977949 — intervention group
Group type: COMPARATOR
Intervention: Intravenous AMP
Number of subjects: 55
Study 1977949 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized beta 2‐agonists
Number of subjects: 55
Study 343788 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg)
Number of subjects: 0
Study 343788 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizole (2.5 mg)
Number of subjects: 0
Study 343788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31370668 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐mL intra‐articular injection of atelocollagen (BioCollagen group)
Number of subjects: 200
Study 31370668 — intervention group
Group type: COMPARATOR
Intervention: Saline (Placebo group)
Number of subjects: 200
Study 31899823 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) for 6 months
Number of subjects: 37
Study 31203242 — intervention group
Group type: EXPERIMENTAL
Intervention: Molidustat
Number of subjects: 150
Study 31203242 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa
Number of subjects: 150
Study 28207497 — intervention group
Group type: EXPERIMENTAL
Intervention: High hsCRP levels with OSA
Number of subjects: 1835
Study 28207497 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hsCRP levels with OSA
Number of subjects: 1835
Study 28207497 — intervention group
Group type: EXPERIMENTAL
Intervention: High hsCRP levels without OSA
Number of subjects: 1835
Study 28207497 — intervention group
Group type: COMPARATOR
Intervention: Low hsCRP levels without OSA
Number of subjects: 1835
Study 25439774 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised training with a cardiothoracic surgeon or fellow (n=15)
Number of subjects: 45
Study 25439774 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised training (n=15)
Number of subjects: 45
Study 25439774 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 45
Study 23305083 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (20 mg rabeprazole and 1 g amoxicillin for the first week, followed by 20 mg rabeprazole, 500 mg clarithromycin, and 500 mg metronidazole for the second week)
Number of subjects: 164
Study 23305083 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy (20 mg rabeprazole, 1 g amoxicillin, 500 mg clarithromycin, and 500 mg metronidazole for 2 weeks)
Number of subjects: 164
Study 21067292 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 60
Study 21067292 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone (control group)
Number of subjects: 60
Study 19581544 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with height shorter than 145 cm
Number of subjects: 3189
Study 19581544 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with mid‐upper arm circumference smaller than 21.5 cm
Number of subjects: 3189
Study 19581544 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborns with head circumference greater than 33.5 cm
Number of subjects: 3189
Study 19581544 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants born to mothers shorter than 145 cm weighing 3300 g
Number of subjects: 3189
Study 16756218 — intervention group
Group type: EXPERIMENTAL
Intervention: Written material provided during counselling (n = 24)
Number of subjects: 50
Study 16756218 — intervention group
Group type: COMPARATOR
Intervention: Systematic counselling without written material (n = 26)
Number of subjects: 50
Study 16756218 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients
Number of subjects: 50
Study 16756218 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient satisfaction
Number of subjects: 50
Study 16756218 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall of details about the cataract surgery procedure
Number of subjects: 50
Study 16756218 — intervention group
Group type: EXPERIMENTAL
Intervention: Legal requirements for informed consent
Number of subjects: 50
Study 15082697 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated equine estrogen (CEE)
Number of subjects: 10739
Study 11735817 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation tubes
Number of subjects: 187
Study 11735817 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 187
Study 9156377 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium (500 mg every 12 hours)
Number of subjects: 16
Study 9156377 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 16
Study 9113121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 0
Study 9113121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 10 mg
Number of subjects: 0
Study 3534201 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental treatment
Number of subjects: 32
Study 3534201 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 3534201 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 32
Study 30442261 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Seldinger technique
Number of subjects: 120
Study 30442261 — intervention group
Group type: COMPARATOR
Intervention: Seldinger technique
Number of subjects: 120
Study 26682695 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise group (60-min sessions three times a week for 16 weeks)
Number of subjects: 200
Study 26682695 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 23286558 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT), 11 to 13 sessions
Number of subjects: 3
Study 22100355 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary cognitive behavioral treatment program
Number of subjects: 61
Study 22100355 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 61
Study 15942709 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lafutidine
Number of subjects: 22
Study 15942709 — intervention group
Group type: COMPARATOR
Intervention: 20 mg rabeprazole
Number of subjects: 22
Study 12197452 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 681
Study 12197452 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 681
Study 12197452 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nefazodone/CBASP
Number of subjects: 681
Study 10331896 — intervention group
Group type: EXPERIMENTAL
Intervention: 12x30 s at 175% PP
Number of subjects: 20
Study 10331896 — intervention group
Group type: EXPERIMENTAL
Intervention: 12x2 min at 90% PP
Number of subjects: 20
Study 10331896 — intervention group
Group type: EXPERIMENTAL
Intervention: 8x4 min at 85% PP
Number of subjects: 20
Study 10331896 — intervention group
Group type: EXPERIMENTAL
Intervention: 12x60 s at 100% PP
Number of subjects: 20
Study 10331896 — intervention group
Group type: EXPERIMENTAL
Intervention: 4x8 min at 80% PP
Number of subjects: 20
Study 7777129 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with epilepsy
Number of subjects: 215
Study 7777129 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 215
Study 7777129 — intervention group
Group type: COMPARATOR
Intervention: Medical personnel observations
Number of subjects: 215
Study 2148632 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA treatment with mild exercise
Number of subjects: 12
Study 2148632 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with mild exercise
Number of subjects: 12
Study 2148632 — intervention group
Group type: COMPARATOR
Intervention: MPA treatment
Number of subjects: 12
Study 6780292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 15
Study 6780292 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 15
Study 31834099 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW (150 mg·kg body mass tyrosine)
Number of subjects: 8
Study 31834099 — intervention group
Group type: EXPERIMENTAL
Intervention: MED (300 mg·kg body mass tyrosine)
Number of subjects: 8
Study 31834099 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH (400 mg·kg body mass tyrosine)
Number of subjects: 8
Study 31834099 — intervention group
Group type: COMPARATOR
Intervention: PLA (0 mg tyrosine)
Number of subjects: 8
Study 29486896 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill-based stance-slip perturbation training protocol
Number of subjects: 0
Study 29486896 — intervention group
Group type: COMPARATOR
Intervention: Placebo training protocol (Control)
Number of subjects: 0
Study 28746178 — intervention group
Group type: EXPERIMENTAL
Intervention: High CMV viral load (>2.52 log copies/mL)
Number of subjects: 76
Study 28746178 — intervention group
Group type: COMPARATOR
Intervention: Low CMV viral load (≤2.52 log copies/mL)
Number of subjects: 76
Study 28746178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CMV-specific T-cell responses (<5 spots/2.0 × 10 PBMC)
Number of subjects: 76
Study 28746178 — intervention group
Group type: COMPARATOR
Intervention: High CMV-specific T-cell responses (≥5 spots/2.0 × 10 PBMC)
Number of subjects: 76
Study 28746178 — intervention group
Group type: EXPERIMENTAL
Intervention: High CMV viral load and low CMV-specific T-cell responses
Number of subjects: 76
Study 28746178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CMV viral load and low CMV-specific T-cell responses
Number of subjects: 76
Study 28746178 — intervention group
Group type: EXPERIMENTAL
Intervention: High CMV viral load and high CMV-specific T-cell responses
Number of subjects: 76
Study 28746178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CMV viral load and high CMV-specific T-cell responses
Number of subjects: 76
Study 24866870 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 77
Study 24866870 — intervention group
Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 77
Study 23139359 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/d atorvastatin
Number of subjects: 100
Study 23139359 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/d atorvastatin
Number of subjects: 100
Study 20980412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (aimed at weight reduction, healthy diet, and increased physical activity) lasting for 4 years (range 1-6 years)
Number of subjects: 522
Study 20980412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 522
Study 20980412 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 522
Study 17874029 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU/day vitamin D3
Number of subjects: 338
Study 17874029 — intervention group
Group type: EXPERIMENTAL
Intervention: 4200 IU/week vitamin D3
Number of subjects: 338
Study 17874029 — intervention group
Group type: EXPERIMENTAL
Intervention: 18,000 IU/month vitamin D3
Number of subjects: 338
Study 17874029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 16154544 — intervention group
Group type: EXPERIMENTAL
Intervention: D-alanine (100 mg/kg/day)
Number of subjects: 32
Study 16154544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 14633532 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple preincisional analgesic therapy (rofecoxib 50 mg PO, 0.25% bupivacaine/0.5% lidocaine field block, ketamine 0.2 mg/kg IV)
Number of subjects: 34
Study 14633532 — intervention group
Group type: COMPARATOR
Intervention: Placebo PO before surgery
Number of subjects: 34
Study 10923937 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal thermistors
Number of subjects: 6
Study 9414355 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced sign incorporating human factor principles (colour, signal word panel, icons/pictorial, explicit wording)
Number of subjects: 0
Study 9414355 — intervention group
Group type: EXPERIMENTAL
Intervention: Original sign
Number of subjects: 0
Study 9414355 — intervention group
Group type: EXPERIMENTAL
Intervention: Two other signs (not specified)
Number of subjects: 0
Study 9414355 — intervention group
Group type: COMPARATOR
Intervention: No-sign period (control)
Number of subjects: 0
Study 1347763 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg xamoterol twice daily
Number of subjects: 12
Study 1347763 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg xamoterol twice daily
Number of subjects: 12
Study 1347763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1347763 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol (100 mg and 200 mg)
Number of subjects: 12
Study 3896701 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen administration
Number of subjects: 0
Study 3896701 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 30208475 — intervention group
Group type: EXPERIMENTAL
Intervention: aP vaccine plus HBV (n = 221)
Number of subjects: 440
Study 30208475 — intervention group
Group type: COMPARATOR
Intervention: HBV only (control group; n = 219)
Number of subjects: 440
Study 30444092 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed irrigation aspiration sanation
Number of subjects: 128
Study 30444092 — intervention group
Group type: COMPARATOR
Intervention: Conventional drainage
Number of subjects: 128
Study 24442160 — intervention group
Group type: EXPERIMENTAL
Intervention: First-reader computer-aided detection (CAD) followed by fast 2-dimensional review (DR FR-CAD)
Number of subjects: 182
Study 24442160 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-reader CAD (SR CAD)
Number of subjects: 182
Study 24442160 — intervention group
Group type: COMPARATOR
Intervention: Unassisted reading
Number of subjects: 182
Study 24442160 — intervention group
Group type: EXPERIMENTAL
Intervention: Double reading with first-reader CAD
Number of subjects: 182
Study 22370444 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g WBE/d
Number of subjects: 63
Study 22370444 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g WBE/d
Number of subjects: 63
Study 22370444 — intervention group
Group type: COMPARATOR
Intervention: 0 g WBE/d (placebo)
Number of subjects: 63
Study 19920806 — intervention group
Group type: EXPERIMENTAL
Intervention: NCX-1000
Number of subjects: 11
Study 19920806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 18540008 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase (rHuPH20)
Number of subjects: 135
Study 18540008 — intervention group
Group type: COMPARATOR
Intervention: Bovine-derived Sigma hyaluronidase
Number of subjects: 135
Study 18540008 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 135
Study 18540008 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed transfers
Number of subjects: 135
Study 18540008 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfers of only embryos from rHuPH20 treatment
Number of subjects: 135
Study 18540008 — intervention group
Group type: COMPARATOR
Intervention: Transfers of only embryos from bovine hyaluronidase treatment
Number of subjects: 135
Study 15935238 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 201
Study 15935238 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 201
Study 15935238 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing mood stabilizer therapy
Number of subjects: 201
Study 14583180 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis
Number of subjects: 6
Study 14583180 — intervention group
Group type: COMPARATOR
Intervention: Group E (diabetes patients with ASO undergoing hemodialysis)
Number of subjects: 6
Study 10319523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular Health Education Program (CHEP)
Number of subjects: 146
Study 10319523 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 146
Study 8740607 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (dose escalated from 25 mg to 100 mg per day over 4 weeks)
Number of subjects: 15
Study 8740607 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 15
Study 8740607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1721814 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% HES 200/0.5 + Naftidrofuryl
Number of subjects: 2
Study 1721814 — intervention group
Group type: COMPARATOR
Intervention: 6% HES 200/0.5 + Naftidrofuryl
Number of subjects: 2
Study 7046784 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole by intramuscular injection immediately before operation
Number of subjects: 100
Study 7046784 — intervention group
Group type: COMPARATOR
Intervention: No antibacterial cover (Control)
Number of subjects: 100
Study 31177635 — intervention group
Group type: EXPERIMENTAL
Intervention: Theatre Improvisation Training to Promote Social Cognition (TIPS) - 18 weekly 2-hour group sessions led by a theatre director and actor-assistant.
Number of subjects: 36
Study 31177635 — intervention group
Group type: COMPARATOR
Intervention: Control group (CR controls who were not enrolled in the study but completed follow-up assessments using the same methods).
Number of subjects: 36
Study 31523988 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-Based Primary Care Project (intervention group)
Number of subjects: 30460
Study 31523988 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30460
Study 27855297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led dementia education and knowledge translation programme
Number of subjects: 85
Study 27855297 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 85
Study 25050468 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV pp65 messenger RNA‐loaded autologous monocyte‐derived dendritic cells (DC) administered intradermally at a weekly interval for 4 weeks
Number of subjects: 7
Study 25050468 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV pp65 messenger RNA‐loaded autologous monocyte‐derived dendritic cells (DC)
Number of subjects: 7
Study 23388087 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with virtual reality
Number of subjects: 300
Study 23388087 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training without virtual reality (active control)
Number of subjects: 300
Study 21114605 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg once daily
Number of subjects: 701
Study 21114605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study 19236376 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential deferiprone-deferoxamine (DFO-DFP)
Number of subjects: 213
Study 19236376 — intervention group
Group type: COMPARATOR
Intervention: Deferiprone (DFP) alone
Number of subjects: 213
Study 17599426 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (titrated to 40 mg/day if necessary) plus placebo
Number of subjects: 5518
Study 17599426 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (titrated to 40 mg/day if necessary) plus active fenofibrate 160 mg/day (or 54 mg/day if eGFR 30 to <50 mL/min per 1.73 m2)
Number of subjects: 5518
Study 15533894 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl palmitate supplementation (25,000, 50,000, or 75,000 IU daily)
Number of subjects: 41
Study 15533894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41